MedPath

Moxifloxacin

Generic Name
Moxifloxacin
Brand Names
Avelox, Moxeza, Vigamox
Drug Type
Small Molecule
Chemical Formula
C21H24FN3O4
CAS Number
151096-09-2
Unique Ingredient Identifier
U188XYD42P
Background

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions
Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Associated Therapies
-
Clinical Trials
Related News

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: cangrelor
Drug: placebo
Drug: moxifloxacin
First Posted Date
2008-06-18
Last Posted Date
2012-01-18
Lead Sponsor
The Medicines Company
Target Recruit Count
67
Registration Number
NCT00699504
Locations
🇺🇸

Charles River Clinical Services NW, Tacoma, Washington, United States

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

Phase 4
Completed
Conditions
Intravitreal Injection Patients
Interventions
Drug: Vigamox
First Posted Date
2008-06-04
Last Posted Date
2019-08-07
Lead Sponsor
Illinois Retina Associates
Target Recruit Count
22
Registration Number
NCT00690313
Locations
🇺🇸

Illinois Retina Associates, Harvey, Illinois, United States

Effects of Single Oral Dose Dapagliflozin QT Study

First Posted Date
2008-06-03
Last Posted Date
2012-03-21
Lead Sponsor
AstraZeneca
Target Recruit Count
36
Registration Number
NCT00688493
Locations
🇺🇸

Research Site, Baltimore, Maryland, United States

Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: AZD3480
Drug: PLACEBO
Drug: Moxifloxacin
First Posted Date
2008-05-29
Last Posted Date
2008-09-25
Lead Sponsor
AstraZeneca
Target Recruit Count
75
Registration Number
NCT00686179

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: placebo
Drug: lixivaptan
Drug: moxifloxacin
First Posted Date
2008-05-12
Last Posted Date
2011-06-21
Lead Sponsor
CardioKine Inc.
Target Recruit Count
298
Registration Number
NCT00675701
Locations
🇺🇸

Research Site 1, Austin, Texas, United States

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: exenatide
Drug: Moxifloxacin
Drug: Placebo
First Posted Date
2008-05-06
Last Posted Date
2015-02-24
Lead Sponsor
AstraZeneca
Target Recruit Count
70
Registration Number
NCT00672399
Locations
🇬🇧

Reseach Site, Derriford, Plymouth, United Kingdom

🇬🇧

Research Site, Leeds, West Yorkshire, United Kingdom

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: immediate release guanfacine hydrochloride
Drug: moxifloxacin
Drug: Placebo
First Posted Date
2008-05-06
Last Posted Date
2021-06-14
Lead Sponsor
Shire
Target Recruit Count
83
Registration Number
NCT00672984
Locations
🇺🇸

Charles River Clinical Services Northwest, Inc., Tacoma, Washington, United States

Moxifloxacin vs. Polytrim for Conjunctivitis

Phase 4
Completed
Conditions
Conjunctivitis
Interventions
Drug: polytrim
Drug: moxifloxacin
First Posted Date
2007-12-27
Last Posted Date
2016-01-18
Lead Sponsor
University of Rochester
Target Recruit Count
124
Registration Number
NCT00581542
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

Phase 4
Completed
Conditions
Bacterial Infections
Eye Infections
Interventions
Drug: Moxifloxacin
Drug: Azithromycin
First Posted Date
2007-11-28
Last Posted Date
2011-09-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
48
Registration Number
NCT00564447

Study Evaluating the Effect of Lecozotan SR on the QTc Interval

Phase 1
Completed
Conditions
Alzheimer Disease
Healthy
First Posted Date
2007-07-11
Last Posted Date
2007-12-28
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Registration Number
NCT00499642
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy